体外研究 (In Vitro) |
Mcl1 Degrader-1 (AUTAC) 相对于 Bcl2 和 Bclxl 选择性结合 Mcl1。 Mcl1 Degrader-1 (100 nM-10 μM; 24-48 h) 可在体外 U266B1 细胞中以剂量和时间依赖的方式选择性降解 Mcl1,但不降解 Bcl2 或 Bclxl,同时还能激活自噬。 Mcl1 Degrader-1 (5 μM; 24 h) 需要自噬才能在 U266B1 细胞中降解 Mcl1。 Mcl1 Degrader-1 (0.1-10 μM; 24-72 h) 可降低 U266B1 和 RPMI-8226 多发性骨髓瘤细胞的活力并诱导细胞死亡,该作用呈时间依赖性;在 U266B1 细胞中作用 48 h 时其 IC50 为 5 μM。 Mcl1 Degrader-1 (10 μM; 24 h) 可在 U266B1 细胞中使 Mcl1 与 Beclin1 解离,并提高 Beclin1 的磷酸化水平,从而激活依赖 Beclin1 的自噬。 Mcl1 Degrader-1 (5-10 μM; 16-24 h) 可在 U266B1 细胞中促进 Mcl1 的 K63 连接泛素化及其与 p62/SQSTM1 的结合,进而与 LC3B 共定位以实现选择性自噬降解。 Mcl1 Degrader-1 (5 μM; 24-72 h) 降解 Mcl1 并诱导 U266B1 细胞发生凋亡性细胞死亡的过程需要 p62/SQSTM1、TRAF6 和 UBC13 的参与;对这些蛋白进行基因敲低后,该化合物的活性会被消除,这一结果证实了上述结论。 Mcl1 Degrader-1 (5 μM; 16-72 h) 联合 Carfilzomib (MS-D41075) 在 U266B1 细胞中增强 Mcl1 降解的过程依赖于 NRF1、功能性自噬 (通过 ATG5) 以及 p62/SQSTM1。 Mcl1 Degrader-1 (500 nM-5 μM; 16-72 h) 在野生型及蛋白酶体抑制剂耐药的多发性骨髓瘤和 NSCLC 细胞中,可通过自噬流的增强来被 Carfilzomib 提升其 Mcl1 降解作用。 Mcl1 Degrader-1 (5 μM; 72 h) 与 Carfilzomib 可协同降低野生型及蛋白酶体抑制剂耐药的多发性骨髓瘤和非小细胞肺癌 (NSCLC) 细胞的活力并诱导其凋亡,且该协同作用依赖于 p62/SQSTM1。
Western Blot Analysis
| Cell Line: |
U266B1 multiple myeloma cells |
| Concentration: |
100 nM, 500 nM, 1 μM, 5 μM, 10 μM (Mcl1 AUTAC); 5 μM (Mcl1 AUTAC, Mcl1-binding moiety); 10 μM (FBnG) |
| Incubation Time: |
24 h, 48 h (Mcl1 AUTAC); 24 h (individual components, starvation) |
| Result: |
Reduced Mcl1 protein levels in a dose- and time-dependent manner, with no observable effect on Bcl2 or Bclxl. Increased LC3 I/II levels, indicating autophagy activation. Showed no effect on Mcl1 expression when used as individual components; starvation-induced autophagy also did not reduce Mcl1 levels. |
Western Blot Analysis
| Cell Line: |
U266B1 multiple myeloma cells, ATG5-knockdown U266B1 multiple myeloma cells |
| Concentration: |
5 μM (Mcl1 AUTAC); 20 μM (CQ); 1 mM (3-MA) |
| Incubation Time: |
24 h |
| Result: |
Rescued Mcl1 degradation when combined with CQ or 3-MA. Led to greater LC3II accumulation when combined with CQ compared to CQ alone. Alleviated Mcl1 degradation in ATG5-knockdown cells. |
Cell Viability Assay
| Cell Line: |
U266B1 and RPMI-8226 multiple myeloma cells |
| Concentration: |
0.1, 0.5, 1, 5, 10 μM (Mcl1 AUTAC); 5 μM (Mcl1 AUTAC, Mcl1-binding moiety, FBnG) |
| Incubation Time: |
24 h, 48 h, 72 h (Mcl1 AUTAC); 24 h (individual components, starvation) |
| Result: |
Reduced cell viability in a time-dependent manner, with an IC50 of 5 μM after 48 h in U266B1 cells and 10 μM after 48 h in RPMI-8226 cells. Induced approximately 50% cell death at 48 h and 60% at 72 h in U266B1 cells. Caused robust accumulation of cleaved caspase 3 and cleaved PARP at 24 and 48 h. Showed no caspase 3 cleavage when used as individual components; starvation also did not induce caspase 3 cleavage. |
Western Blot Analysis
| Cell Line: |
U266B1 multiple myeloma cells |
| Concentration: |
10 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced the binding between Mcl1 and Beclin1. Increased the phosphorylation of Beclin1. |
Immunofluorescence
| Cell Line: |
U266B1 multiple myeloma cells |
| Concentration: |
5, 10 μM |
| Incubation Time: |
16 h, 24 h |
| Result: |
Induced clear colocalization of Mcl1 with K63-linked ubiquitin, p62/SQSTM1, and LC3B. Increased the binding of Mcl1 to both K63-linked ubiquitin and p62/SQSTM1. |
Western Blot Analysis
| Cell Line: |
U266B1 multiple myeloma cells, p62/SQSTM1-knockdown U266B1 multiple myeloma cells, TRAF6-knockdown U266B1 multiple myeloma cells, UBC13-knockdown U266B1 multiple myeloma cells |
| Concentration: |
5 μM |
| Incubation Time: |
24 h, 72 h |
| Result: |
Abolished Mcl1 degradation and reduced accumulation of cleaved caspase 3 and cleaved PARP in p62/SQSTM1-knockdown cells. Suppressed Mcl1 degradation and PARP cleavage in TRAF6 or UBC13-knockdown cells. Reduced U266B1WT cell viability by over 50%, but blunted this cytotoxic response in p62/SQSTM1, TRAF6, or UBC13-knockdown cells. |
Western Blot Analysis
| Cell Line: |
multiple myeloma (U266B1, MM.1S, RPMI-8226, AMO-1, U266B1R, AMO-1R) and non-small cell lung cancer (NCI-H1975, NCI-H1975R) cells |
| Concentration: |
500 nM-5 μM (Mcl1 AUTAC); 2.5 nM, 10 nM (carfilzomib) |
| Incubation Time: |
16 h, 24 h, 48 h, 72 h |
| Result: |
Enhanced Mcl1 degradation across all tested cell lines, including proteasome inhibitor-resistant lines, when combined with CFZ. Increased LC3I/II levels, indicating enhanced autophagic flux, when combined with CFZ. Showed more pronounced reduction in Mcl1 levels, increased accumulation of LC3B and LAMP1, and greater colocalization of Mcl1 with these markers in U266B1 cells when combined with CFZ. |
Western Blot Analysis
| Cell Line: |
U266B1 multiple myeloma cells, NRF1-knockout U266B1 multiple myeloma cells, ATG5-knockdown U266B1 multiple myeloma cells, p62/SQSTM1-knockdown U266B1 multiple myeloma cells |
| Concentration: |
5 μM (Mcl1 AUTAC); 10 nM (carfilzomib) |
| Incubation Time: |
16 h, 24 h, 72 h |
| Result: |
Lost enhanced Mcl1 degradation by the Mcl1 AUTAC + CFZ combination in NRF1-knockout cells, with diminished LC3I/II levels. Attenuated Mcl1 degradation by the Mcl1 AUTAC + CFZ combination in ATG5-knockdown cells. Completely abolished Mcl1 degradation induced by the Mcl1 AUTAC + CFZ combination in p62/SQSTM1-knockdown cells. Showed standalone Mcl1 degradation, autophagy induction, and cell death that were not dependent on NRF1. |
|